
Primary CNS Lymphoma
Treatment should be within a clinical trial where possible. There is no standard regimen for PCNSL but treatment should include high dose methotrexate (3-5 doses of ≥ 3 g/m2 delivered over a maximum of 2-3 hours at interval of not more than 2-3 weeks). The efficacy is improved by adding rituximab. Such treatment should be based on established protocols. See:
- Grommes, C. and L. M. DeAngelis (2017). "Primary CNS Lymphoma." J Clin Oncol 35(21): 2410-2418.
- Illerhaus, G., Kasenda, B. (2016). "High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial." Lancet Haematol 3: e388-97.
- Ferreri, A.J., Cwynarski, K. (2016). "Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial." Lancet Haematol 3: e217-27.
Topic Code: 1603